Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 0.49 |
| ▸ | JAK1 | P23458 | 6/20 | 0.49 |
| ▸ | JAK3 | P52333 | 6/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.46 |
| ▸ | SYK | P43405 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PRKACA | P17612 | 1/20 | 0.43 |
| ▸ | PRKACG | P22612 | 1/20 | 0.43 |
| ▸ | PRKACB | P22694 | 1/20 | 0.43 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12148001 | 1.00 | JAK2 (0.49) | JAK2JAK1JAK3ROCK2ROCK1 | |
| SCHEMBL12147952 | 0.89 | JAK3 (0.47) | JAK2JAK1JAK3SYKCYP2C9 | |
| SCHEMBL1369763 | 0.89 | JAK2 (0.52) | JAK2JAK1JAK3SYKCYP2C9 | |
| SCHEMBL1369292 | 0.88 | JAK2 (0.46) | JAK2JAK1JAK3SYKCYP2C9 | |
| SCHEMBL15755458 | 0.88 | ROCK2 (0.51) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| SCHEMBL1371429 | 0.87 | SYK (0.49) | JAK2JAK1JAK3ROCK2ROCK1 | |
| SCHEMBL1370909 | 0.87 | JAK3 (0.50) | JAK2JAK1JAK3ROCK2ROCK1 | |
| SCHEMBL1370498 | 0.86 | JAK2 (0.49) | JAK2JAK1JAK3SYKMAPT | |
| SCHEMBL1369466 | 0.85 | JAK2 (0.51) | JAK2JAK1JAK3SYKCYP2C9 | |
| SCHEMBL12147871 | 0.85 | JAK2 (0.51) | JAK2JAK1JAK3SYKCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN (US) | 2011-11-24 | — | — | US | claimed |
| US-20140155376-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155376-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| WO-2011144585-A1 | PYRROLO [2, 3 - B] PYRAZINE - 7 - CARBOXAMIDE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-11-24 | — | — | WO | disclosed |
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, JAK2 | JAK2 3/4885JAK1 5/4885JAK3 7/4885 |
| US-20140155376-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK2 | JAK2 3/4885JAK1 5/4885JAK3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.